°®¶¹´«Ã½

Corrected Material:

Consolidated Financial Report for Fiscal 2010 (fiscal year ended March 31, 2011, Japan Standard), Section (3) Research & Development Projects, Alliances, and Other Events, Page 8, Lines 14-17.

Corrected Contents: *corrected part is underlined.

(Original)

â—¯ A Phase III study of the anticancer agent E7080 (VEGF receptor tyrosine kinase /multi-kinase inhibitor) for thyroid cancer was initiated in the U.S. In addition, a Phase III study for melanoma was initiated in Europe following commencement of the study in the U.S. A Phase II study in patients with glioma is also ongoing in the U.S.

(Corrected)

â—¯ A Phase III study of the anticancer agent E7080 (VEGF receptor tyrosine kinase /multi-kinase inhibitor) for thyroid cancer was initiated in the U.S. In addition, Phase II studies for endometrial cancer and melanoma were initiated in Europe following commencement of the studies in the U.S. A Phase II study in patients with glioma is also ongoing in the U.S.